Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

IGC Pharma Inc

IGC ✓ COMPLIANT ☆ Track — members

NYSE American · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$0.30

▲ +1.29%

Market Cap $31.08M · Vol 120.23K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$31.08M

Micro Cap

Div Yield

N/A

EPS Growth

+14.93%

YoY

RSI (14)

68.55

Momentum

Beta

0.51

vs Market

52W High

$0.50

40.20% below

52W Low

$0.24

26.19% above

Volume

120.23K

Avg 35.40K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

86.62%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, IGC Pharma Inc (IGC) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does IGC pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+16.06%

+11.54%

-0.40%

+16.33%

YTD

+5.83%

-17.28%

-12.41%

-81.50%

Financials & Valuation

TTM · Annual

Total Revenue	$869.00K
Net Income	$-4,146,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	N/A · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	21.58
P/B	N/A
P/FCF	N/A
EPS Growth	+14.93%
Outstanding Shares	104.37M

Technical Indicators

50-Day SMA	$0.27
200-Day SMA	$0.29
RSI (14)	68.55
Beta	0.51
52-Week High	$0.50
52-Week Low	$0.24

Volume Today	120.23K
Avg Daily Volume (30D)	35.40K
Relative Volume	3.40x
Volatility (10D)	30.04
Volatility (30D)	40.21
Free Float	86.62%

Analyst Consensus

BUY

Current Price $0.30

Mean Target $4.00

52W Low$0.24 52W High$0.50

Current

Target

$0.24 $0.50

Current Analyst target

+1,243.18% upside potential · 2 analysts

Identifiers

ExchangeNYSE American

FIGIBBG001SQQKX0

ISINUS45408X3089

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 14, 2025

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

IGC Pharma, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) to develop treatments for Alzheimer's and metabolic disorders. The Company's lead asset, IGC-AD1, is a cannabinoid-based therapy is in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia. The Company’s pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. The Company integrates AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. It is also developing a Multimodal Interpretable Transformer for Alzheimer’s Disease (MINT-AD). MINT-AD leverages diverse data sources, including brain scans, genetics, lifestyle, and cognitive metrics, to produce clinically interpretable risk profiles and forecast decline trajectories.